Regression of Melanoma Nodules in a Patient Treated With Ranitidine

Thomas J Smith, Jeffrey W. Clark, Martin B. Popp

Research output: Contribution to journalArticle

Abstract

Human malignant melanoma may regress spontaneously or with immunotherapy, such as Calmette-Guerin bacillus, interferon alfa, interleukin-2, and interleukin-2 plus lymphokine-activated killer cells. Histamine type 2 receptor antagonists can modulate immune function by inhibiting suppressor T-cell induction and activity, and melanoma regressions have been reported after the use of cimetidine with coumarin or interferon alfa. This article describes the complete regression of melanoma nodules in a patient treated with ranitidine hydrochloride, another histamine type 2—receptor antagonist. Ranitidine and cimetidine should be considered to be possibly active immunotherapeutic agents in the design and evaluation of clinical trials.

Original languageEnglish (US)
Pages (from-to)1815
Number of pages1
JournalArchives of Internal Medicine
Volume147
Issue number10
DOIs
Publication statusPublished - 1987
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Internal Medicine

Cite this